Two new drugs for skin and skin structure infections

Medical Letter on Drugs and Therapeutics

Volumn 56, Issue 1449, 2014, Pages 73-75

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); CEFAZOLIN; CEFTAROLINE FOSAMIL; CEFTRIAXONE; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DALVANCE; DAPTOMYCIN; DOXYCYCLINE; LINEZOLID; PENICILLIN DERIVATIVE; SIVEXTRO; TEDIZOLID; TELAVANCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANAPHYLAXIS; DIARRHEA; DIZZINESS; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NAUSEA; NOTE; OPTIC NERVE DISEASE; PERIPHERAL NEUROPATHY; PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; SKIN INFECTION; SKIN STRUCTURE INFECTION; SOFT TISSUE INFECTION; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ANIMALS; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; ORGANOPHOSPHATES; OXAZOLES; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCAL INFECTIONS; TEICOPLANIN;

EID: 84906095081     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (13)

1. Telavancin (Vibativ) for gram-positive skin infections. Med Lett Drugs Ther 2010; 52:1.
2. Linezolid (Zyvox). Med Lett Drugs Ther 2000; 42:45.
3. DL Stevens et al. Executive summary: practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infec Dis 2014; 59:147.
4. Drugs for MRSA skin and soft-tissue infections. Med Lett Drugs Ther 2014; 56:39.
5. HF Chambers. Pharmacology and the treatment of complicated skin and skin-structure infections. N Engl J Med 2014; 370:22-38.
6. HW Boucher et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 2014; 370:21-69.
7. O Urbina et al. Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections. Drug Des Devel Ther 2013; 7:243.
8. RN Jones et al. TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens. J Antimicrob Chemother 2009; 63:716.
9. SD Brown and MM Traczewski. Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges. Antimicrob Agents Chemother 2010; 54:20-63.
10. L Vera-Cabrera et al. In vitro activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis. Antimicrob Agents Chemother 2006; 50:3170.
11. P Prokocimer et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 2013; 309:559.
12. GJ Moran et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTAB-LISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 2014; 14:696.
13. S Flanagan et al. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob Agents Chemother 2013; 57:30-60.